ACADIA Pharmaceuticals to Host Conference Call and Webcast on November 27, 2012 at 8:00 AM EST to Present Top-Line Results from

  ACADIA Pharmaceuticals to Host Conference Call and Webcast on November 27,
  2012 at 8:00 AM EST to Present Top-Line Results from Its Pivotal Phase III
  Pimavanserin Parkinson’s Disease Psychosis Trial

Business Wire

SAN DIEGO -- November 26, 2012

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused
on innovative treatments that address unmet medical needs in neurological and
related central nervous system disorders, today announced that it will host a
conference call and webcast at 8:00 a.m. Eastern Time on Tuesday, November 27,
2012 to present the top-line results from its pivotal Phase III trial with
pimavanserin in patients with Parkinson’s disease psychosis (PDP).

The conference call may be accessed by dialing 866-783-2140 for participants
in the U.S. or Canada and 857-350-1599 for international callers (reference
passcode 26249437). A telephone replay of the conference call may be accessed
through December 11, 2012 by dialing 888-286-8010 for callers in the U.S. or
Canada and 617-801-6888 for international callers (reference passcode
47904115). The conference call also will be webcast live on ACADIA’s website,
www.acadia-pharm.com, under the investors section and will be archived there
until December 11, 2012.

About Pimavanserin

Pimavanserin is ACADIA’s proprietary small molecule that acts selectively as
an antagonist/inverse agonist on serotonin 5-HT[2A] receptors and is in Phase
III development as a potential first-in-class treatment for Parkinson’s
disease psychosis. Pimavanserin can be taken orally as a tablet once-a-day.
ACADIA discovered and holds worldwide rights to pimavanserin.

About Parkinson’s Disease Psychosis

According to the National Parkinson’s Foundation, about one million people in
the United States and from four to six million people worldwide suffer from
Parkinson’s disease. Parkinson’s disease psychosis, or PDP, is a debilitating
disorder that develops in up to 60 percent of patients with Parkinson’s
disease. Currently, there is no FDA-approved therapy to treat PDP in the
United States. PDP, commonly consisting of visual hallucinations and
delusions, substantially contributes to the burden of Parkinson’s disease and
deeply affects the quality of life of patients. PDP is associated with
increased caregiver stress and burden, nursing home placement, and increased
morbidity and mortality. There is a large unmet medical need for new therapies
that will effectively treat PDP without compromising motor control in patients
with Parkinson’s disease.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatments that
address unmet medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by pimavanserin,
which is in Phase III development as a potential first-in-class treatment for
Parkinson's disease psychosis. ACADIA also has clinical-stage programs for
chronic pain and glaucoma in collaboration with Allergan, Inc. and two
preclinical programs directed at Parkinson’s disease and other neurological
disorders. All of ACADIA’s product candidates are small molecules that emanate
from discoveries made using its proprietary drug discovery platform. ACADIA
maintains a website at www.acadia-pharm.com to which ACADIA regularly posts
copies of its press releases as well as additional information and through
which interested parties can subscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature
are forward-looking statements. These statements include but are not limited
to statements related to the progress and timing of ACADIA’s drug discovery
and development programs, either alone or with a partner, including clinical
trials and the results of clinical trials, and the benefits to be derived from
ACADIA’s product candidates, in each case including pimavanserin. These
statements are only predictions based on current information and expectations
and involve a number of risks and uncertainties. Actual events or results may
differ materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in drug
discovery, development and commercialization, and collaborations with others,
and the fact that past results of clinical trials may not be indicative of
future trial results. For a discussion of these and other factors, please
refer to ACADIA’s annual report on Form 10-K for the year ended December31,
2011 as well as ACADIA’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. This
caution is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof, except as required by law.

Contact:

ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive Vice President,
Chief Financial Officer and Chief Business Officer
(858) 558-2871